Further studies on the human pancreatic binary complexes involving procarboxypeptidase A

M. Moulard, Thierry Michon, Brigitte Kerfelec, Catherine Chapus

► To cite this version:

M. Moulard, Thierry Michon, Brigitte Kerfelec, Catherine Chapus. Further studies on the human pancreatic binary complexes involving procarboxypeptidase A. FEBS Letters, 1990, 261 (1), pp.179-183. hal-02709529

HAL Id: hal-02709529

<https://hal.inrae.fr/hal-02709529>

Submitted on 1 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Further studies on the human pancreatic binary complexes involving procarboxypeptidase A

Maxime Moulard, Thierry Michon*, Brigitte Kerfelec and Catherine Chapus

Centre de Biochimie et de Biologie Moléculaire du CNRS, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 9, France and

*Laboratoire de Biochimie et Technologie des Protéines I.N.R.A., Rue de la Géraudière, 44026 Nantes Cedex 03, France

Received 1 December 1989

In contrast to procarboxypeptidase B which has always been reported to be secreted by the pancreas as a monomer, procarboxypeptidase A occurs as a monomer and/or associated to one or two functionally different proteins, depending on the species. Recent studies showed that, in the human pancreatic secretion, procarboxypeptidase A is mainly secreted as a 44 kDa protein involved in at least three different binary complexes. As previously reported, two of these complexes associated procarboxypeptidase A to either a glycosylated truncated protease E or zymogen E. In this paper, we identified proelastase 2 as the partner of procarboxypeptidase A in the third complex, thus reporting for the first time the occurrence of a proelastase 2/procarboxypeptidase A binary complex in vertebrates. Moreover, from N-terminal sequence analyses, the 44 kDa procarboxypeptidase A involved in these complexes was identified as being of the A₁ type. Only one type of procarboxypeptidase B, the B₁ type, has been detected in the analyzed pancreatic juices, thus emphasizing the previously observed genetic differences between individuals.

Human pancreas; Procarboxypeptidase; Protease E; Proelastase 2; Protein complex

1. INTRODUCTION

Various molecular forms of secreted proCPA, resulting from its ability to bind to other pancreatic serine endopeptidases, have been reported. In some ruminant species, proCPA is secreted as a ternary complex [1,2] in association with a chymotrypsinogen of the C-type [3] and a truncated protease E [4,5]. Binary complexes in which proCPA is associated to either probably a chymotrypsinogen of the C-type or to zymogen E have been described in the sei whale [6] and in the pig [7], respectively. In the human secretion, two major binary complexes in which proCPA is associated to either a glycosylated truncated protease E (32 kDa) or an unidentified 28 kDa protein have been reported [8]. A binary form in which proCPA is bound to zymogen E has also been described in human pancreas [9]. On the other hand, in several species such as dog [10], dogfish [11], lungfish [12] and horse [2], proCPA is secreted as a monomer. However, in some species,

proCPA is secreted in two states. Thus, besides the above-mentioned binary forms, the porcine [7] and human [9] secretions contain monomeric proCPA.

Besides this heterogeneity of molecular forms of secretion, two types of proCPA (A₁ and A₂), differing by their substrate specificities and primary sequences and resulting from gene duplication, allelic polymorphism and/or differential processing of the mature enzyme have been reported in man [13] and rat [14]. Two types of proCPB (B₁ and B₂) have also been reported in man [13].

In this paper, we report that in the human pancreatic juices investigated, the 28 kDa protein associated to proCPA is a proelastase 2. Moreover, from N-terminal sequence analyses, the human 44 kDa proCPA of the two binary complexes was shown to belong to the A₁ type and the proCPB to the B₁ type.

2. MATERIALS AND METHODS

2.1. Materials

Lyophilized pancreatic juices devoid of any proteolytic activity were a generous gift from Dr Lombardo (CBBM, CNRS, Marseille). DMMA and t-Boc Ala ONp were purchased from Sigma (St Louis, MO, USA). HPLA and HA were from Bachem (Budendorf, Switzerland). Benzamidine was from Fluka (Zurich, Switzerland). All chemicals used in this study were of analytical grade and were used without further purification. Ultrogel Aca 54 and DE-Trisacryl were from IBF (Villeneuve-la-Garenne, France) and Superose 12 from Pharmacia (Uppsala, Sweden).

2.2. Methods

2.2.1. Filtration of lyophilized human pancreatic juice on Aca 54 Ultrogel

Correspondence address: C. Chapus, Centre de Biochimie et de Biologie Moléculaire du CNRS, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 9, France

Abbreviations: DMMA, 2,3 dimethylmaleic anhydride; t-Boc Ala N-t-Boc-L-alanine *p*-nitrophenyl ester; HPLA, hippuryl-L-phenyllactic acid and HA, hippuryl-L-arginine; ProCPA, procarboxypeptidase A; proCPB, procarboxypeptidase B; CPA, carboxypeptidase A; CPB, carboxypeptidase B

Enzymes: (pro)carboxypeptidase A (EC 3.4.17.1); (pro)carboxypeptidase B (EC 3.4.17.2); pro(elastase), (zymogen E) protease E (EC 3.4.21.36); trypsin (EC 3.4.21.4)

This filtration was performed as reported in [8].

2.2.2. Activity measurements

CPA activity was potentiometrically measured after tryptic activation as previously reported [15] using a 1 mM HPLA solution as substrate. In order to avoid the inhibitory effect of the activation peptide, monomeric proCPA was first acylated by DMMA before tryptic activation [15]. The CPB activity was determined spectrophotometrically after tryptic activation using a 1 mM HA solution according to [16]. The protease E and elastase 2 activities were determined potentiometrically at pH 7.5 and 25°C using a 10 mM *N*-acetyl L-tyrosine ethyl ester solution as substrate in a 1 mM Tris-HCl buffer containing 0.1 M NaCl. Spectrophotometric assays for protease E and elastase 2 activities were also performed at pH 6.0 and 25°C using 0.8 mM t-Boc Ala ONp as substrate according to [17].

2.2.3. Purification and dissociation of the binary complexes

The fractions containing the binary complexes eluted from the above-mentioned gel filtration column were purified as reported [8]. The dissociation of the two binary complexes was performed by treatment with DMMA as previously reported [18]. The free dimethylmaleylated subunits of the complexes were then separated by molecular sieving on an Aca Ultrogel 54 Ultrogel (1 cm × 4 m) or on a Superose 12 column using a Fast Protein Liquid Chromatograph (Pharmacia). The columns were equilibrated and eluted with a 0.1 M sodium bicarbonate buffer, pH 9.0, containing 0.4 M NaCl and 1 mM benzamidine. Deacylation of the subunits was obtained by dialysis at 4°C for 48 h at pH 7.0 for proCPA and for 24 h at pH 6.0 for the other two proteins.

2.2.4. Purification of monomeric procarboxypeptidase B

The fractions containing proCPB resulting from Aca 54 gel filtration of lyophilized human pancreatic juice were pooled, extensively dialyzed against a 20 mM Tris-HCl buffer, pH 8.0, containing 50 mM NaCl and 1 mM benzamidine, and then chromatographed on a DE-Trisacryl column (2 × 15 cm) equilibrated in the same buffer. The elution was performed using the same buffer. CPA and CPB activities were tested as reported above, all along the elution profile.

2.2.5. Gel electrophoresis

Electrophoresis in the presence of SDS was carried out in 10–15% polyacrylamide gel as described by Laemmli [19] using a Phast gel ap-

paratus (Pharmacia). The proteins were stained with 0.25% Coomassie brilliant blue and destained in acetic acid/ethanol/water mixtures (1.5:1.0:17.5, v/v).

2.2.6. N-terminal sequence analyses

N-terminal sequence analyses were performed by stepwise Edman degradation using a gas phase sequencer (Applied Biosystems, model 470A). The resulting phenylthiohydantoin were analyzed by HPLC using a C₁₈ column (Brownlee, 5 mm, 2.1 × 220 mm). They were eluted by a methanol gradient (10–46%) in a 5 mM sodium acetate buffer, pH 4.84.

3. RESULTS

3.1. Purification and characterization of the two binary complexes

The two major binary complexes, isolated from gel filtration of human pancreatic juice were further purified to homogeneity by chromatography on DE-Trisacryl as reported [8], and then dissociated using the DMMA method elaborated for the dissociation of the bovine proCPA-S6 ternary complex [18]. The complete separation of the free acylated partners (proCPA, 32 and 28 kDa proteins) was achieved by molecular sieving on Aca 54 Ultrogel or Superose 12 at pH 9.0. For each binary complex, two well-separated peaks were obtained and the proteins were deacylated as described in section 2. The deacylated protein solutions were found homogeneous by SDS gel analysis and investigated without further purification.

As previously reported [8], the 32 kDa protein associated to the 44 kDa proCPA in the first complex was devoid of any activity towards specific substrates. This glycoprotein was unambiguously identified to a truncated protease E.

Table 1

Comparison of N-terminal sequences of proCPA from various species

	1	5	10	15	20	25
rat proCPA ₁ [21]	NENFVGHQVLRISA	DEA	QVQKVKELE			
man 44 kDa proCPA ^a	K--D-----		V-----			
ox proCPA [22]	K--D-----		T-----	E-----	T-----	
pig proCPA [23]	K--D-----		V D-----			
rat proCPA ₂ [14]	Q--T-----	D-----	E--IPSH-E--	IRTLLQ-----		

^a44 kDa proCPA from the two human binary complexes (proCPA / truncated protease E and proCPA / proelastase 2). The rat proCPA₁ sequence is used as reference

Table 2

Comparison of the N-terminal sequences of the CPA from different species

	1	5	10	15	20	25
rat CPA ₁ [21]	ALSTDSFN	YATYHTL	DEIYEFMDLL			
man CPA ^a	x x x-----	T-----	E-----	D--L-----		
ox CPA [7]	--R-----	NT-----	D-----			
pig CPA [24]	x x T--ST-----		E-----	B-----		
rat CPA ₂ [14]	ERGGN*	FEA-----	E-----	QE-----	N--	

^aCPA resulting from tryptic activation of proCPA/proelastase 2 binary complex. The rat CPA is used as reference. Deletions (*) have been inserted in order to optimize sequence alignment. x, unidentified residues

Fig.1. DE-Trisacryl chromatography of monomeric procarboxypeptidases. The monomeric procarboxypeptidases were purified on a DE-Trisacryl column as indicated in section 2. Flow rate, 35 ml/h; fraction volume, 3.5 ml. Carboxypeptidase A (—) and B (---) potential activities were determined as described (see section 2) after tryptic activation.

The isolated 28 kDa protein was found inactive towards the various serine endopeptidase substrates. However, after incubation with catalytic amounts of trypsin, the protein displayed an activity towards both *N*-acetyl L-tyrosine ethyl ester and t-boc Ala ONp compatible with an elastase 2 specificity. In order to further identify this 28 kDa protein, the N-terminal sequence of the trypsin activated form has been carried out. The following sequence, extending to residue 34, was obtained:

1 5 10 15 20 25 30
XGDPTYPYVTRVVGEEARPNSWPWQVSLQYSS

Except for the first amino acid which has not been identified (X), this sequence is identical to that of the corresponding sequence of human proelastase 2 deduced from cDNA sequencing by Shirasu et al. [20]. This finding confirms the activity studies and allows us to

unambiguously identify the 28 kDa protein to the zymogen of human elastase 2.

3.2. Identification of the proCPA type involved in the two binary complexes

In order to identify the type of the 44 kDa proCPAs involved in the two binary complexes, the N-terminal sequences of the isolate proCPAs have been determined and compared to those of proCPA from various species (table 1). These two sequences extending to residue 25, were found to be strictly identical and to correspond to the A₁ type as shown by their higher homology to rat proCPA₁ than rat proCPA₂ [14].

Comparisons with proCPAs from other species showed that human and porcine proCPAs are very homologous (for the first 25 residues a single substitution located in position 15 was observed) and also, that bovine and porcine proCPAs are likely to be of the A₁ type.

The N-terminal sequence of the CPA resulting from the tryptic activation of the proCPA involved in the proelastase 2 binary complex, has also been determined and compared to those of various CPAs (table 2). This sequence although uncompleted, further supports the fact that the human 44 kDa proCPA belongs to the A₁ type.

3.3. Isolation and characterization of monomeric procarboxypeptidase B

ProCPB was eluted from the gel filtration chromatography of human pancreatic juice at the elution volume expected for a monomeric form [8]. Further purification of the protein by chromatography on DE-Trisacryl at pH 8.0 (fig.1) yielded two peaks.

The first major peak was shown to possess a high potential CPB activity and a very low potential CPA activity. Since CPB has been shown to exhibit a low activity towards synthetic CPA substrates, it cannot be ascertained that this peak contains proCPA traces. In the minor second peak the percent of proCPA potential activity relative to proCPB significantly increased. The CPA activity observed under this peak is likely to come from the minor 47 kDa proCPA form, first identified in man by Scheele et al. [13], since only a 47 kDa band was detected by SDS gel electrophoresis.

The occurrence of monomeric proCPB in the first

Table 3

Comparison of N-terminal sequences of proCPB from various species

	1	5	10	15	20	25
man proCPB	H	H	G	G	E	H
man proCPB ₁ [9]	H	H	G	G	E	H
man proCPB ₂ [9]	H	H	G	G	E	H
rat proCPB [21]	H	H	G	G	E	H
pig proCPB [23]	H	H	G	G	E	H
lungfish proCPB [25]	H	H	G	G	E	H

The human proCPB sequence is used as reference. x, unidentified residues

peak was confirmed by N-terminal sequence analysis. The sequence of the first 25 residues of the chain is presented in table 3 and compared to those of other proCPBs. It appears strictly identical to those of human proCPB₁ and proCPB₂ described by Pascual et al. [9] except for residue 22. In contrast to human proCPB₂ which has a glutamine residue in position 22, the presence of a histidine residue in this position in the monomeric proCPB allows us to postulate that this protein is of the B₁ type and confirms the occurrence of, at least, two forms of the enzyme in man.

During the N-terminal sequence determination of proCPB, another sequence (20 amino acids) very similar to that of human CPB₁ [26] was also detected (data not shown). The presence of the contaminant (CPB₁ in the proCPB sample resulted from a non-controlled activation of the zymogen. The type of the proCPB under the minor peak was not investigated.

4. DISCUSSION

In the human pancreatic juices studied, the major form of proCPA has a M_r of 44 000 and occurs in two binary associations with functionally different proteins. One of them has been identified as a glycosylated truncated protease E [8], and in this paper, we report that the second proCPA complex involves proelastase 2. This finding is the first evidence for the occurrence of a binary complex involving proCPA and proelastase 2. Similar amounts of each binary complex were detected, suggesting that the truncated protease E and proelastase 2 compete for the same site on proCPA, with similar affinities.

The complexes were dissociated using DMMA, which induces electrostatic repulsion between the subunits. This strongly suggests that the binding of the truncated protease E and proelastase 2 to proCPA occurs through ion pairing as previously observed for the binding of truncated protease E to bovine proCPA [18].

Pascual et al. [9] described, in human pancreas, the presence of a single binary complex associating the 44 kDa proCPA to zymogen E, the immediate precursor of protease E. However, it must not be ruled out that these discrepancies might result from genetic differences between individuals. Yet, the presence of a glycosylated truncated protease E in human pancreas has also been reported by Guy-Crotte et al. [27].

The presence of proCPA in association with other serine proteases in man and other species raises the question of the physiological significance of such complexes. In vitro, no dissociation has been observed during proteolytic activation of the human (data not shown) and bovine complexes [15]. Up to now, whether or not proteolytic activation induces in vivo the dissociation of these complexes remains unknown. It can be expected that these associations improve the protein digestion by physical effects such as stabilization of

the proCPA as described for the bovine complex [4].

The 44 kDa proCPA in the human binary complexes investigated in these studies was shown to belong to the A₁ type. Seemingly the free or associated 44 kDa proCPA forms isolated from human pancreas [9] are likely to be of the same A₁ type. This suggests that although different molecular secreted forms of secreted proCPA have been reported, human proCPA mainly occurs as a single 44 kDa form belonging to the A₁ type.

ProCPB was found secreted as a monomer with a M_r of 47 000. From N-terminal sequence analysis, the major form of proCPB can be classified into the B₁ type since it contains an histidine residue in position 22. Pascual et al. [9] reported a glutamine residue in the same position in human proCPB₂. Except for this residue, the sequences of the first 25 amino acids of the B₁ and B₂ chains were identical, supporting the hypothesis of allelomorphism rather than gene duplication. The absence of a significant amount of proCPB₂ in our analyzed human pancreatic juices is consistent with previous observations by Scheele et al. [13] and emphasizes the genetic differences between individuals.

Acknowledgements: We wish to acknowledge E. Foglizzo for skillful technical assistance. We are also greatly indebted to J. Bonicel for N-terminal sequence analyses.

REFERENCES

- [1] Yamasaki, M., Brown, J.R., Cox, D.J., Greenshields, R.N., Wade, R.D. and Neurath, H. (1963) *Biochemistry* 2, 859-866.
- [2] Kerfelec, B., Chapus, C. and Puigserver, A. (1985) *Eur. J. Biochem.* 151, 531-538.
- [3] Peanasky, R.J., Gratecos, D., Baratti, J. and Rovey, M. (1969) *Biochim. Biophys. Acta* 181, 82-92.
- [4] Kerfelec, B., Cambillau, C., Puigserver, A. and Chapus, C. (1986) *Eur. J. Biochem.* 157, 531-538.
- [5] Cambillau, C., Kerfelec, B., Sciaky, M. and Chapus, C. (1988) *FEBS Lett.* 232, 91-95.
- [6] Yoneda, T. (1980) *Comp. Biochem. Physiol.* 67B, 81-86.
- [7] Kobayashi, R., Kobayashi, Y. and Hirs, C.H.W. (1978) *J. Biol. Chem.* 253, 5526-5530.
- [8] Moulard, M., Kerfelec, B., Mallet, B. and Chapus, C. (1989) *FEBS Lett.* 250, 166-170.
- [9] Pascual, R., Burgos, F.J., Salva, M., Soriano, F., Mendez, E. and Avilés, F.X. (1989) *Eur. J. Biochem.* 179, 609-616.
- [10] Marchis-Mouren, G., Charles, M., Ben Abdeljlil, A. and Desnuelle, P. (1961) *Biochim. Biophys. Acta* 50, 186-188.
- [11] Lacko, A.G. and Neurath, H. (1970) *Biochemistry* 9, 4680-4690.
- [12] Reeck, G.R., Winter, W.P. and Neurath, H. (1970) *Biochemistry* 9, 1398-1403.
- [13] Scheele, G., Bartelt, D. and Bieger, W. (1981) *Gastroenterology* 80, 461-473.
- [14] Gardell, S.J., Craik, C.S., Clauser, E., Goldsmith, E.J., Stewart, C.B., Graf, M. and Rutter, W.J. (1988) *J. Biol. Chem.* 263, 17828-17836.
- [15] Chapus, C., Kerfelec, B., Foglizzo, E. and Bonicel, J. (1987) *Eur. J. Biochem.* 166, 379-385.
- [16] Folk, J.E., Piez, K.A., Carroll, W.R. and Gladner, J.A. (1960) *J. Biol. Chem.* 235, 2272-2277.
- [17] Largman, C., Broderick, J.W. and Geokas, M.C. (1976) *Biochemistry* 15, 2491-2500.

- [18] Kerfelec, B., Chapus, C. and Puigserver, A. (1984) *Biochem. Biophys. Res. Commun.* 121, 162-167.
- [19] Laemmli, U.R. (1970) *Nature (Lond.)* 227, 680-685.
- [20] Shirasu, Y., Yoshida, H., Matsuki, S., Takemura, K., Ikeda, N., Shimada, Y., Ozawa, T., Mikayama, T., Iijima, H., Ishida, A., Sato, Y., Tamai, Y., Tanaka, J. and Ikenaga, H. (1987) *J. Biochem.* 102, 1555-1563.
- [21] Clauser, E., Gardell, S.J., Craik, C.S., MacDonald, R.J. and Rutter, W.J. (1988) *J. Biol. Chem.* 263, 17837-17845.
- [22] Foglizzo, E., Bonicel, J., Kerfelec, B., Granon, S. and Chapus, C. (1988) *Biochem. Biophys. Acta* 954, 183-188.
- [23] Avilès, F.X., Vendrell, J., Burgos, F.J., Soriano, F. and Mendez, E. (1985) *Biochem. Biophys. Res. Commun.* 130, 97-103.
- [24] Bradshaw, R.A., Ericsson, L.H., Walsh, R.A. and Neurath, H. (1969) *Proc. Natl. Acad. Sci. USA* 63, 1389-1394.
- [25] Reeck, G.R. and Neurath, H. (1972) *Biochemistry* 11, 3947-3955.
- [26] Guy-Crotte, O., Barthe, C., Basso, D., Fournet, B. and Figarella, C. (1988) *Biochem. Biophys. Res. Commun.* 156, 318-322.